2015 Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
10/13/15Audentes Therapeutics Raises $65 Million In Series C Financing
Leading Healthcare Investors Provide Funding to Advance AAV Gene Therapy Pipeline in Serious, Rare Diseases to Key Clinical Milestones and to Build Internal Manufacturing CapabilitiesSAN FRANCISCO, CA – October 13, 2015 – Audentes Therapeutics, Inc., a biotechnology company committed to the development and commercialization of gene therapy products for patients with serious, rare diseases, today announced the closing of an oversubscribed $65 million Series C financing. The financing was co-led b... 
Printer Friendly Version
09/29/15Audentes Therapeutics Expands Senior Leadership Team
Natalie Holles Appointed Chief Operating Officer, Thomas Soloway Appointed Chief Financial Officer and Kevin Baker, Ph.D. Appointed Senior Vice President, Preclinical DevelopmentSAN FRANCISCO, CA – September 29, 2015 – Audentes Therapeutics, Inc., a biotechnology company committed to the development and commercialization of gene therapy products for patients with serious, rare diseases, today announced the addition of three accomplished biopharmaceutical executives to its leadership team. Natali... 
Printer Friendly Version
09/01/15Audentes Therapeutics Acquires Cardiac Gene Therapy Company Cardiogen Sciences
Audentes Expands Portfolio to Include AAV Gene Therapy for Rare, Genetic Cardiac Diseases including CASQ2-CPVT, an Inherited Arrhythmia with a High Risk of MortalitySAN FRANCISCO, CA – September 1, 2015 – Audentes Therapeutics, Inc., a biotechnology company committed to the development and commercialization of gene therapy products for patients with serious, rare diseases, today announced the acquisition of Cardiogen Sciences, Inc., a biotechnology company focused on the discovery and developmen... 
Printer Friendly Version
08/26/15Audentes Therapeutics Receives Orphan Drug Designation for AT001 for the Treatment of X-Linked Myotubular Myopathy in the US and Europe
SAN FRANCISCO, CA – August 26, 2015 – Audentes Therapeutics, Inc., a biotechnology company committed to the development and commercialization of gene therapy products for patients with serious, rare diseases, today announced that AT001, an investigational product in development for the treatment of X-Linked Myotubular Myopathy (XLMTM), has been granted orphan designation by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).XLMTM is a rare, severe, inherited disord... 
Printer Friendly Version
05/14/15Audentes Therapeutics To Participate In 2015 Piper Jaffray Genomerx Symposium & 1×1 Day
SAN FRANCISCO, CA – May 14, 2014 – Audentes Therapeutics, Inc., a biotechnology company committed to the development and commercialization of gene therapy products for patients with serious, rare diseases, today announced that Matthew R. Patterson, President and Chief Executive Officer, and John T. Gray, PhD, Vice President, Research and Development, will participate in the 2015 Piper Jaffray GenomeRx Symposium & 1×1 Day at The New York Palace Hotel in New York City on May 20-21, 2015.About ... 
Printer Friendly Version
05/11/15Audentes Therapeutics Announces New Data To Be Presented At American Society Of Gene And Cell Therapy Annual Meeting
Compelling additional preclinical data further support therapeutic potential of gene therapy products to treat X-Linked Myotubular Myopathy and Pompe DiseaseSAN FRANCISCO, CA – May 11, 2015 – Audentes Therapeutics, Inc., a biotechnology company committed to the development and commercialization of gene therapy products for patients with serious, rare diseases, today announced that new data from its lead development programs will be presented at the 18th Annual Meeting of the American Society of ... 
Printer Friendly Version
04/21/15Audentes Therapeutics Appoints Stephen Squinto, Ph.d. To Its Board Of Directors
SAN FRANCISCO, CA – April 21, 2015 – Audentes Therapeutics, Inc., a biotechnology company committed to the development and commercialization of gene therapy products for patients with serious, rare diseases, today announced the appointment of Stephen Squinto, Ph.D., to the company’s Board of Directors. Dr. Squinto, a co-founder of Alexion Pharmaceuticals, Inc., will serve as an independent director to Audentes.“Steve is a pioneer in bringing innovative therapies to patients with rare diseases. A... 
Printer Friendly Version
02/26/15Audentes Therapeutics Joins Global Organizations In Celebrating Rare Disease Day® 2015
New Audentes Patient Advocacy Website Created to Serve Patient CommunitySAN FRANCISCO, CA – February 26, 2015 – Audentes Therapeutics, Inc., a biotechnology company committed to the development and commercialization of gene therapy products for patients with serious, rare diseases, today announced its support for Rare Disease Day®, to be held on February 28th, 2015.  The theme of this year’s Rare Disease Day is Living with a Rare Disease.  In honor of the day, Audentes is pleased to an... 
Printer Friendly Version